Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Acrivon Therapeutics Inc’s stock clocked out at $1.15, up 4.55% from its previous closing price of $1.10. In other words, the price has increased by $4.55 from its previous closing price. On the day, 1.6 million shares were traded.
Ratios:
To gain a deeper understanding of ACRV’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.17 and its Current Ratio is at 11.17. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Ladenburg Thalmann Upgraded its Neutral to Buy on September 16, 2024, while the target price for the stock was maintained at $16.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 30 ’25 when PERCEPTIVE ADVISORS LLC sold 437,881 shares for $1.41 per share. The transaction valued at 617,412 led to the insider holds 3,403,025 shares of the business.
PERCEPTIVE ADVISORS LLC sold 298,886 shares of ACRV for $400,507 on May 01 ’25. The 10% Owner now owns 3,104,139 shares after completing the transaction at $1.34 per share. On Apr 25 ’25, another insider, PERCEPTIVE ADVISORS LLC, who serves as the 10% Owner of the company, sold 1,054,669 shares for $1.95 each. As a result, the insider received 2,056,605 and left with 4,306,189 shares of the company.
Stock Price History:
Over the past 52 weeks, ACRV has reached a high of $10.16, while it has fallen to a 52-week low of $1.09. The 50-Day Moving Average of the stock is -55.59%, while the 200-Day Moving Average is calculated to be -80.60%.
Shares Statistics:
A total of 31.35M shares are outstanding, with a floating share count of 21.75M. Insiders hold about 30.62% of the company’s shares, while institutions hold 56.74% stake in the company.
